THU0199 Tofacitinib, An Oral Janus Kinase Inhibitor, in The Treatment of Rheumatoid Arthritis: Changes in Lymphocytes and Lymphocyte Subset Counts and Reversibility after Up To 8 Years of Tofacitinib Treatment

M. Lamba,A. Hazra,E.B. Lee,R. van Vollenhoven,J. Hodge,S. Krishnaswami,E. Choy,A. Anisfeld,L. Wang,P. Biswas,S. Menon,J.D. Clark,I. Lazariciu

doi:10.1136/annrheumdis-2016-eular.2134

THU0199 Tofacitinib, An Oral Janus Kinase Inhibitor, in The Treatment of Rheumatoid Arthritis: Changes in Lymphocytes and Lymphocyte Subset Counts and Reversibility after Up To 8 Years of Tofacitinib Treatment

M. Lamba, A. Hazra + Show 11 more

https://doi.org/10.1136/annrheumdis-2016-eular.2134

Copy DOI

Journal: Annals of the Rheumatic Diseases	Publication Date: Jun 1, 2016
Citations: 5

Affiliation: Pfizer (United States), Seoul National University, Amsterdam UMC Location VUmc, Cardiff University

#Pfizer Inc #Absolute Lymphocyte Counts + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

BackgroundTofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Cytokines involved in lymphocyte development, function and homeostasis are known to signal through JAKs.ObjectivesTo characterise...

Full Text

Published version (

Free)

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

R Discovery Prime

R Discovery Prime

THU0199 Tofacitinib, An Oral Janus Kinase Inhibitor, in The Treatment of Rheumatoid Arthritis: Changes in Lymphocytes and Lymphocyte Subset Counts and Reversibility after Up To 8 Years of Tofacitinib Treatment

Abstract

Talk to us

Similar Papers

More From: Annals of the Rheumatic Diseases

Lead the way for us